Who owns Brainstorm Cell Therapeutics?
- Ticker: BCLI
- CUSIP Number: 10501e201
Tip: Access positions for across all investors
Analyze quarterly positions in Brainstorm Cell Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Brainstorm Cell Therapeutics stock
Who bought or sold Brainstorm Cell Therapeutics this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Vanguard Group | 1.4M | $389k | 0% | Dec 2023 |
|
Liberty Wealth Management | 340k | $94k | -4% | Dec 2023 |
|
Weaver Consulting Group | 199k | $113k | -5% | Mar 2024 |
|
Caldwell Sutter Capital | 157k | $0 | 0% | Mar 2024 |
|
Abner, Herrman & BrocK | 146k | $82k | 0% | Mar 2024 |
|
Raymond James & Associates | 114k | $64k | -2% | Mar 2024 |
|
ADAR1 Capital Management | 101k | $28k | 100% | Dec 2023 |
|
Ikarian Capital | 90k | $25k | 0% | Dec 2023 |
|
Kingswood Wealth Advisors | 81k | $46k | 100% | Mar 2024 |
|
Citadel Advisors | 77k | $21k | -63% | Dec 2023 |
|
Virtu Financial | 71k | $19k | 100% | Dec 2023 |
|
Jmac Enterprises | 65k | $18k | 0% | Dec 2023 |
|
Barclays | 46k | $12k | 100% | Dec 2023 |
|
Wells Fargo & Company | 30k | $8.1k | -26% | Dec 2023 |
|
Saxony Capital Management | 21k | $5.8k | 100% | Dec 2023 |
|
Creative Planning | 21k | $5.7k | 30% | Dec 2023 |
|
Janney Montgomery Scott | 21k | $6.0k | 2% | Dec 2023 |
|
Professional Financial Advisors | 17k | $4.7k | 0% | Dec 2023 |
|
Zullo Investment Group | 16k | $4.4k | 100% | Dec 2023 |
|
First Affirmative Financial Network | 15k | $8.6k | -3% | Mar 2024 |
|
Nelson, Van Denburg & Campbell Wealth Management | 13k | $3.5k | 0% | Dec 2023 |
|
Socha Financial Group | 12k | $3.4k | 0% | Dec 2023 |
|
Bank of New York Mellon | 12k | $3.3k | 0% | Dec 2023 |
|
Advisor Group Holdings | 11k | $2.9k | -28% | Dec 2023 |
|
HighTower Advisors | 10k | $3.0k | -2% | Dec 2023 |
|
Cypress Capital Management | 10k | $2.7k | 233% | Dec 2023 |
|
Institutional & Family Asset Management | 6.0k | $1.6k | 0% | Dec 2023 |
|
Steward Partners Investment Advisory | 4.2k | $1.1k | -19% | Dec 2023 |
|
Bangor Savings Bank | 4.0k | $2.3k | 0% | Mar 2024 |
|
UBS Group | 2.5k | $683.000000 | -31% | Dec 2023 |
|
EverSource Wealth Advisors | 2.1k | $580.944000 | 100% | Dec 2023 |
|
VisionPoint Advisory Group | 1.9k | $530.906400 | 0% | Dec 2023 |
|
Able Wealth Management | 1.9k | $523.968000 | 100% | Dec 2023 |
|
Bank of America Corporation | 1.1k | $273.302200 | 5% | Dec 2023 |
|
Cranbrook Wealth Management | 1.0k | $565.000000 | 100% | Mar 2024 |
|
Royal Bank of Canada | 544.00 | $0 | -72% | Dec 2023 |
|
D. J. St. Germain | 500.00 | $137.000000 | 0% | Dec 2023 |
|
Bnp Paribas Arbitrage, Snc | 364.00 | $99.008000 | 0% | Dec 2023 |
|
Westside Investment Management | 200.00 | $112.000000 | 0% | Mar 2024 |
|
Mark Sheptoff Financial Planning | 100.00 | $27.000000 | 0% | Dec 2023 |
|
Jpmorgan Chase & Co | 71.00 | $18.999600 | 82% | Dec 2023 |
|
Who sold out of Brainstorm Cell Therapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Gts Securities | Sep 2023 | 203k | $41k |
Moore Capital Management | Sep 2023 | 200k | $40k |
Millennium Management | Sep 2023 | 176k | $35k |
Two Sigma Investments | Sep 2023 | 77k | $15k |
T. Rowe Price Associates | Sep 2023 | 42k | $9.0k |
Two Sigma Securities | Sep 2023 | 40k | $8.1k |
Jane Street | Sep 2023 | 31k | $6.1k |
AE Wealth Management | Sep 2023 | 14k | $2.9k |
Charles Schwab Investment Management | Sep 2023 | 11k | $2.3k |
Harbour Investments | Sep 2023 | 796.00 | $158.961200 |